Mind Medicine shares up as Phase 2b studies continue on medical LSD
Mind Medicine Inc. (MindMed) shares rose 10% in premarket trades on Thursday after the company said patient dosing in its Phase 2b trial is ongoing and offers a "highly attractive commercial opportunity." The clinical sta...